… cisplatin should remain standard treatment of patients with locoregionally advanced head and
neck squamous cell … oropharyngeal cancer treated with RT plus cetuximab versus cisplatin…

… concurrent with cisplatin plus fluorouracil is a … cancer. However, the treatment toxicity and
the survival outcomes of definitive concurrent chemoradiotherapy (dCRT) with cisplatin plus …

… cisplatin … cisplatin in chemoradiotherapy protocols of non-nasopharyngeal LA-SCCHN,
prompted us to conduct a set of meta-analyses scrutinizing high-dose and low-dose cisplatin …

… to three-weekly cisplatin. Three-weekly cisplatin chemoradiotherapy should be considered
the standard approach in the management of locally advanced head and neck cancer. …

… Prospective study of cetuximab, carboplatin, and radiation therapy for patients with locally
advanced head and neck squamous cell cancer unfit for cisplatin. Int J Radiat Oncol Biol Phys …

… cancer, 26,30 chemoradiotherapy with weekly cisplatin has … suggested that chemoradiotherapy
with weekly cisplatin at a … studies of chemoradiotherapy with weekly cisplatin indicated …

… All patients received standard high-dose cisplatin chemoradiotherapy. The primary endpoint
was the proportion of patients with locoregional control 18 months after chemoradiotherapy, …

… therapy of choice comprised of concurrent chemoradiotherapy with cisplatin at 100 mg/m 2
on day … , again difficult to apply or compare to our patient cohort with squamous cell cancers. …

… intent chemoradiotherapy using either high-dose cisplatin (… LDC were defined by the initial
cisplatin dose ranges (80–120 … cisplatin dose, we also tabulated the total amount of cisplatin …

… Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of
care for locally advanced head and neck squamous cell … cannot complete cisplatin because of …